Anzeige
Meldung des Tages: Diese Defence-Aktie übernimmt Cashflow-starken Fertiger – und baut eigene Produktionsmacht auf

Immunic News

Aktie
WKN:  A2PHD4 ISIN:  US4525EP1011 US-Symbol:  IMUX Branche:  Biotechnologie Land:  USA
1,405 $
-0,04 $
-2,77%
1,2194 € 15:08:43 Uhr
Depot/Watchlist
Marktkapitalisierung *
47,04 Mio. €
Streubesitz
61,15%
KGV
-0,79
Index-Zuordnung
-

Immunic News

01.10.25 - EQS
EQS-News: Immunic to Participate in Scientific and Investor Conferences in October
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Investor Conferences in October 01.10.2025 / 12:30 CET/CEST The issuer is solely ...
01.10.25 - PR Newswire
Immunic to Participate in Scientific and Investor Conferences in October
Immunic to Participate in Scientific and Investor Conferences in October PR Newswire
25.09.25 - EQS
EQS-News: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Conference/Study results Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in ...
25.09.25 - PR Newswire
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis PR Newswire
09.09.25 - EQS
EQS-News: Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Patent Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple ...
09.09.25 - PR Newswire
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis PR Newswire
04.09.25 - EQS
EQS-News: Immunic to Participate in Investor and Scientific Conferences in September
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in September 04.09.2025 / 12:30 CET/CEST The issuer is solely ...
04.09.25 - PR Newswire
Immunic to Participate in Investor and Scientific Conferences in September
Immunic to Participate in Investor and Scientific Conferences in September PR Newswire
07.08.25 - EQS
EQS-News: Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update 07.08.2025 / 12:30 CET/CEST ...
07.08.25 - PR Newswire
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire
24.06.25 - EQS
EQS-News: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Issuer: Immunic AG / Key word(s): Study/Study results Immunic Reports New, Positive Long-Term Open-​Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus ...
24.06.25 - PR Newswire
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
Immunic Reports New, Positive Long-Term Open-​Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-​Remitting Multiple Sclerosis PR ...
05.06.25 - EQS
EQS-News: Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Issuer: Immunic AG / Key word(s): Study/Study results Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional ...
05.06.25 - PR Newswire
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER Trial in Progressive MS
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Relapsing MS and Presents Additional Data Underlining Positive Outcome of Phase 2 CALLIPER ...
03.06.25 - PR Newswire
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire
02.06.25 - EQS
EQS-News: Immunic to Participate in Investor, Scientific and Industry Conferences in June
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Investor, Scientific and Industry Conferences in June 02.06.2025 / 12:30 CET/CEST The issuer is solely ...
02.06.25 - PR Newswire
Immunic to Participate in Investor, Scientific and Industry Conferences in June
Immunic to Participate in Investor, Scientific and Industry Conferences in June PR Newswire
29.05.25 - PR Newswire
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering PR Newswire
28.05.25 - PR Newswire
Immunic, Inc. Announces Proposed Public Offering
Immunic, Inc. Announces Proposed Public Offering PR Newswire
02.05.25 - EQS
EQS-News: Immunic to Participate in Scientific and Industry Conferences in May
Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in May 02.05.2025 / 12:30 CET/CEST The issuer is solely responsible ...

Newssuche

Videos

newspaper
10.03.26 -2,51%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »